Ficlatuzumab is a humanized monoclonal antibody that specifically targets and neutralizes the biological activity of human hepatocyte growth factor (HGF), by inhibiting HGF, Ficlatuzumab effectively blocks c-Met receptor-mediated downstream signaling pathways responsible for cancer cell proliferation, migration, and invasion, demonstrating applicable use for the treatment of squamous cell carcinoma.
Purity:
99.00%
CAS Number:
[1174900-84-5]
Target:
c-Met/HGFR
* VAT and and shipping costs not included. Errors and price changes excepted
